Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CCR6 | P51684 | 1/20 | 0.44 |
| ▸ | PRKCA | P17252 | 9/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6330898 | 1.00 | KDM4E (0.49) | KDM4ERAB9AL3MBTL1CCR6PRKCA | |
| SCHEMBL6328042 | 0.98 | KDM4E (0.51) | KDM4ERAB9AL3MBTL1CCR6PRKCA | |
| SCHEMBL6328046 | 0.98 | KDM4E (0.51) | KDM4ERAB9AL3MBTL1CCR6PRKCA | |
| SCHEMBL6325721 | 0.96 | KDM4E (0.50) | KDM4ERAB9AL3MBTL1CCR6PRKCA | |
| SCHEMBL6325723 | 0.96 | KDM4E (0.50) | KDM4ERAB9AL3MBTL1CCR6PRKCA | |
| SCHEMBL6331100 | 0.96 | KDM4E (0.47) | KDM4ERAB9AL3MBTL1CCR6PRKCA | |
| SCHEMBL6331101 | 0.96 | KDM4E (0.47) | KDM4ERAB9AL3MBTL1CCR6PRKCA | |
| SCHEMBL6331719 | 0.94 | KDM4E (0.46) | KDM4ERAB9AL3MBTL1CCR6PRKCA | |
| SCHEMBL6331717 | 0.94 | KDM4E (0.46) | KDM4ERAB9AL3MBTL1CCR6PRKCA | |
| SCHEMBL6325136 | 0.93 | KDM4E (0.54) | KDM4ERAB9AL3MBTL1CCR6PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009928-A1 | Cyclopentanone derivative | ZEON CORPORATION (JP) | 2005-01-13 | — | — | US | disclosed |
| EP-1420005-A1 | CYCLOPENTANONE DERIVATIVE | Zeon Corporation (JP) | 2004-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009928-A1 | Cyclopentanone derivative | PTGIS, CYP51A1, TRPA1 | KDM4E 2486/4885RAB9A 4009/4885L3MBTL1 4713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.